DARA Biosciences Inc

DARA Biosciences — Merger or Acquisition (June 2015)

14 slides from DARA Biosciences's merger presentation, Jun 5, 2015

  1. Slide 1: Proposed Acquisition of DARA BioSciences

    Filed by Midatech Pharma PLC Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: DARA BioSciences, Inc. Commission File No.: 000-23776 Proposed Acquisition of DARA BioSciences 4 June 2015 A

  2. Slide 2: Important Notice

    IMPORTANT NOTICE Neitherthis presentation,the publicationin which it is containednor any copyof it may be madeor transmitted into the United Statesof America(includingits territories or possessions,anystate of the United Statesof Americaand the District of Columbia) (the “United States”). Neither th

  3. Slide 3: Disclaimer

    Disclaimer Certain statements in this presentation may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the expected completion of the acquisitio

  4. Slide 4: Recap on Midatech

    Recap on Midatech Au Gold nanoparticles Strong cash Top-tier Organic, and microspheres position and pharma acquisitive for drug delivery reliable revenue partners growth strategy Key focus Strong pipeline Sector-leading Management on oncology nearing commercial manufacturing with proven viability fa

  5. Slide 5: Emerging specialty pharma company

    Emerging specialty pharma company Midatech intends to generate value from its nanoparticle technology New patented medicines created using its platforms to enhance well known therapeutics Midatechbusiness model has 3 components: 1 2 3 Partner Products Own Products Acquisitions Diabetes / Oncology /

  6. Slide 6: Existing therapeutic areas & key collaborators

    Existing therapeutic areas & key collaborators THERAPEUTIC COLLABORATOR PROGRAMME PROJECT CURRENTLY MARKET AREA REVENUE SIZE** EARNING Endocrinology MonoSol Rx MonoSol Rx MidaSol JV MidaSol JV Transbuccal Insulin Transbuccal GLP1 No (50:50 JV) No (50:50 JV) >$20bn >$6bn Top 6 US Pharma* MidaSol JV T

  7. Slide 7: Existing internal pipeline

    Existing internal pipeline Research Preclinical Phase I Phase II Markets Endocrinology Midaform®Insulin > $ 20bn Q-Octreo > $ 2bn Cancer Glioblastoma > $ 500m Liver > $ 500m CNS/Ocular OpsiSporin $ 640m • Five partnerships with blue chip pharma & specialty pharma in diabetes, cancer & ophthalmology

  8. Slide 8: DARA acquisition enhances Midatech equity story

    DARA acquisition enhances Midatech equity story • Proposed conditional acquisition agreement with DARA BioSciences, Inc. (NASDAQ: DARA) • Oncology supportive care pharmaceutical company • Subject to certain adjustments, Midatech will issue approximately 5.4 million ordinary shares in exchange for th

  9. Slide 9: DARA BioSciences

    DARA BioSciences • DARA is a specialty pharma focused on oncology treatment and supportive care products • Oncology supportive care portfolio of 5 products • Phase 2 Orphan designated NCE for CCIPN / multiple myeloma • Headquarters in Raleigh, NC; US salesforce of approx. 20 • 2014 revenues of $1.9

  10. Slide 10: Highlights of the acquisition

    Highlights of the acquisition • Excellentstrategicfit – strengthensMidatech’sfranchisein oncology • Immediate access to revenue generating product portfolio in cancer supportive care • Provides commercial platform in US • Will enable Midatechto launch its self-developed products, including Q-Octreo,

  11. Slide 11: Strategic rationale – products and salesforce

    Strategic rationale – products and salesforce • International diversification into US adding differentiated and attractive portfolio of oncology supportive care products, including: • Gelclair®, an oral gel indicated for the management and relief of pain due to oral mucositis during cancer treatment

  12. Slide 12: Summary

    Summary • DARA brings access to new products in oncology for potential fast growth and commercial footprint in US • Delivering in-line with strategy as set out at time of IPO to ensure rapid growth and value creation • Leading platform technologies • GNP’s small size and capability of targeting e.g.

  13. Slide 13: Additional Information and Where to Find It

    Additional Information and Where to Find It In connection with the proposed transaction, Midatech will file with the SEC a Registration Statement on Form F-4, which will include the proxy statement of DARA and that also constitutes a prospectus of Midatech under SEC filing rules (the “proxy statemen

  14. Slide 14: Thank you

    Thank you

DARA BioSciences — Merger or Acquisition (June 2015) on 6ix